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Background: Pulmonary thromboembolism (PTE) is among the leading causes 
of death following surgery and/or hospital admission. Role of thrombophilic 
risk factors in the etiology of PTE is well known; But not much data is available 
on their role in severity of PTE. The aim of this study was to investigate the role 
of thrombotic risk factors especially PLA2 polymorphism of platelet 
glycoprotein IIb/IIIa in the severity of PTE. 
Materials and Methods: Genotyping from Factor-V (FVL) and prothrombin 
20210A (PT20210A) mutations were shown to be significant risk factors for PTE 
and recurrent PTE. The plasma concentrations of platelet glycoprotein IIb/IIIa 
PLA2 polymorphism, presence of FVL and PT20210A mutations were studied 
in 37 patients with PTE. 
Results: Eleven of these patients had recurrent PTE. Lung perfusion scans were 
scored according to the percentage of vascular obstruction. Patients who had a 
pulmonary vascular obstruction (PVO) score >50%were compared to those with 
PVO score<50%. There was no significant difference between patients with 
PVO score>50% and those with PVO score<50% with regard to the presence of 
FVL and PT20210A mutations. However, patients with PVO score>50% had a 
significantly higher frequency of platelet glycoprotein IIb/IIIaPLA2 
polymorphism than those with PVO score <50%. 
Conclusion: Our data suggest that presence of PLA2 is associated with an 
increased risk of PTE in the Iranian population. The association between 
recurrent events and coinheritance of more than one thrombophilic genetic risk 
factor shows that such carriers are at a higher risk of PTE. 
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INTRODUCTION 
Pulmonary thromboembolism is a major health 
problem worldwide. The annual incidence of PTE in the 
general population of the Western countries is estimated to 
be 0.1–0.05% (1, 2). There are many well-recognized 
secondary risk factors for PTE. Primary risk factors, also 
known as congenital thrombophilic risk factors, should be 
seriously evaluated in patients with a documented, 
unexplained thrombotic episode. The most commonly 
reported congenital risk factors are the factor-V 1691G-A 
(FVL) mutation, prothrombin20210A (PT20210A) 
mutation, protein-C and -S deficiency and anti-thrombin 
deficiency (3,4) .GP IIIa is a highly polymorphic proteinand 
platelet antigen 1 (PlA1) and 2 (PlA2) are its most common 
allelic isoforms. In PlA2 allele, cytosine replaces thymidine 
in exon2, which is phenotypically translated in the 
substitution of proline for leucine at position 33 of the 
mature GPIIIa (5). A previous in vitro study demonstrated 
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that the PlA2 variant enhanced the binding of GPIIb/IIIa 
receptor to fibrinogen and consequently increased platelet 
aggregation induced by agonists (6). The clinical impact of 
PlA2 polymorphism has been investigated in several 
diseases, in which thrombus formation is a key 
pathogenetic factor. Recently, a high frequency of platelet 
glycoprotein IIb/IIIa PLA2 polymorphism was shown to 
be an independent and dose-dependant risk factor for PTE 
and recurrent PTE (2, 7, 8). In this study, the authors aimed 
to investigate the role of some of the congenital 
thrombophilic risk factors (FVL, PT20210A mutation and 
high platelet glycoprotein IIb/IIIa PLA2 polymorphism 
frequency) in severity of PTE. 
 
MATERIALS AND METHODS 
Patients and controls 
Thirty-seven unrelated patients, 13 males and 24 
females, with a mean age of 53.78 years, were recruited 
from local volunteers with documented PTE and in the 
first step of research were compared with the control 
group of 152 unrelated healthy donors (matched by age 
and sex) with no history of vascular disease were recruited 
from local volunteers (2).  They were recruited from Hajar 
Hospital, Shahrekord, Iran. Ethics committee of 
Shahrekord University of Medical Sciences approved this 
study (2). Patients provided written informed consent 
forms. Patients were clinically diagnosed using the Well’s 
criteria and then PTE was confirmed in all patients by 
high-probability ventilation/perfusion lung scanning 
performed in Shahrekord Omid Center. In some patients 
(nearly 60%) spiral CT of the lung and mediastinum with 
contrast and with PTE protocol was performed in 
Shahrekord Hajar Hospital to rule out other diseases (2). 
Echocardiography was performed for all patients. Eleven 
of them (34.4%) were identified as having documented 
recurrent PTE from the hospital records. The inclusion 
criteria were the incidence of one or more episodes of 
pulmonary embolism at the time of diagnosis (9). Twenty-
three of the patients presented with isolated PTE and nine 
of which had PTE associated with DVT. Of the 37 patients 
studied, nine had no specific risk factor for PTE. In the 
remaining 28 patients, most had more than one risk factor, 
15 had immobility, nine had DVT, nine had obesity, one 
had estrogen compound usage, and two had multiple 
trauma. None had malignancies or familial history of PTE 
or DVT. After diagnosis of PTE, blood samples were 
collected for laboratory studies. Twenty-nine patients 
received anticoagulation therapy with standard heparin, 
followed by warfarin. The remaining eight patients had 
clinically massive PTE and received thrombolytic therapy 
with streptokinase, followed by the same anticoagulation 
therapy. Written informed consent was obtained from each 
patient. 
 
Study design 
Perfusion-ventilation lung scans were performed in 
Shahrekord Omid Center. The clinicians obtaining the 
scans were unaware of the clinical condition of the patient 
at the time of diagnosis.   To assess pulmonary vascular 
obstruction and severity of PTE, pulmonary vascular 
obstruction score (PVOs) was calculated by using a 
technique described by Meyer et al. (10) and Oguzulgen et 
al (11). We used this formula from Each lobe was assigned 
a weight based on the regional distribution of pulmonary 
blood flow in the supine position: right lower lobe 25%, 
right middle lobe 12%, right upper lobe 18%, left lower 
lobe 20%, lingula 12%, and left upper lobe 13%. Perfusion 
within each lobe was estimated from the anterior, posterior 
and oblique views. For each lobe, a semi-quantitative 
perfusion score, from 0–1 (0, 0.25, 0.5, 0.75 and 1), was 
estimated from the film density compared to the 
photodensity of an apparently normal perfused area. Each 
lobar-perfusion score was then calculated by multiplying 
the weight by the perfusion score. The overall perfusion 
score was determined by summing the six separate lobar-
perfusion scores. The percentage of vascular obstruction by 
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perfusion scanning (PVOs) was then calculated as: PVOs 
(%)=(1-overall perfusion score) X100 (10,11).Patients with 
PVOs >50% were compared to those with PVOs<50%, with 
respect to the presence of FVL, PT20210A mutations and 
PLA2 polymorphism.  
Pulmonary thromboembolism was clinically diagnosed 
according to the Well’s criteria and was then confirmed by 
perfusion scan. Spiral CT of the lung and mediastinum 
with contrast and with PTE protocol was performed in 60% 
of patients with doubtful diagnoses. 
 
Sample Collection and DNA Extraction:  
Blood samples were collected from all patients at the 
time of diagnosis. Before the onset of anticoagulation 
therapy, venous blood was collected in 5 ml Vacutainer 
tubes with EDTA. DNA was isolated by the phenol 
chloroform method and quantified using Unico 2100 
spectrophotometer. PCR using genomic DNA followed by 
restriction fragment length polymorphism (RFLP) were 
done to identify each polymorphism (Thermocycler 
ASTEC, PC818, Japan). Primers and restriction enzymes 
were provided by TAG, Copenhagen, Denmark and 
Fermentas, Russia, and summarized in Table 1. The 
thermal cycling conditions are summarized in Table 2. 
DNA sequencing was performed on selected samples to 
confirm the polymorphisms. The FVL mutate detected by 
the amplification of a 267-bp fragment using the specific 
primers. This fragment is digested with 1.5 units of Mn1I 
restriction enzyme to three fragments in wild type (163, 67 
and37 bp). The FVL mutation eliminates a restriction site 
and produces two fragments of 200 and 67 bp. For 
identification of FII G20210A polymorphism, a 345-bp 
fragment is amplified and digested with HindIII  
restriction Enzyme . There is no cleavage site in wild type,  
whereas the mutated allele produces two fragments of 322 
and 23 bp. A 264-bp fragment is amplified and digested to 
two fragments (222 and 42 bp) by MspI restriction enzyme 
in PLA1 polymorphism. Introducing a new cleavage site in 
PLA2 results in three fragments (173, 49 and 42 bp).To 
detect MTHFR C677T polymorphism, a 198-bpfragment is 
digested by Hinf I restriction Enzyme  two fragments of 
175 and 23 bp in the presence of MTHFR C677T 
polymorphism (12). However, there is no cleavage site in 
the   un mutated allele. for diagnosis of PTE lung perfusion 
scan performed and then with formula of PVOs the 
percentage of vascular obstruction by perfusion scanning 
was calculated as: 
PVOs (%)=(1-overall perfusion score)X100 (10,11). 
Statistical analysis: Statistical analysis was performed 
using SPSS version 18. Descriptive statistics were 
employed for patients’ clinical characteristics. The odds 
ratio (OR) was used to assess the strength of association 
between genetic polymorphisms and PTE. Statistical 
significance of genetic distribution as well as patients’ age 
and sex was calculated using independent sample t-test (2). 
 
Table 1. Restriction enzymes and primer sequences 
 
Genetic 
polymorphism 
Restriction 
enzyme 
Primer sequences 
FVL Mn1I F 5 TGC  CCA  GTG  CTT  AAC  AAG  ACC  
A  3  R  5  TGT  TAT CAC  ACT  GGT  GCT  
AA  3 
FIIaG20210A HindIII F 5  TCT  AGA  AAC  AGT  TGC  CTG  GC  
3 R  5  ATA  GCA  CTG GGA  GCA  TTG  
AAG  C 3 
PLA1/PLA2 MspI F 5  TTC  TGA  TTG  CTG  GAC  TTC  TCT  
T 3  R  5  TCT  CTC  CCC  ATG  GCA  AAG  
AGT  3 
MTHFR C677T HinfI F  5  TGA  AGG  AGA  AGG  TGT  CTG  
CGG  GA 3 R  5  AGG  ACG GTG  CGG  
TGA  GAG  TG  3 
 
FVL , Factor V Leiden; MethyleneTetrahydrofolatereductase (MTHFR),  prothrombin 
 
Regression was used to analyze the relationship 
between multiple independent polymorphisms and PTE. 
Mann–Whitney U test was performed for comparison of 
the number of mutations in patients with and without 
recurrent events and family history. All data of genetic 
factors were calculated in comparison to the control group. 
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Table 2. Thermal cycling conditions 
 
Genetic 
polymorphism  
Thermal cycling conditions 
 
FVL 
96 C  for  5min 
6 cycles of 96 C for 1 min ,  58C  for 1 min, 72 C for 1 min 
28 cycles of 96 C for 30 s, 56 C for 30 s, 72 C for 30s 
A  final  extension period of  5 min at 72 C 
FIIG20210A 94C for 5min 
33 cycles of 94C for 30 s, 60C for 45 s, 72C for 60s 
A final extension period of 5 min at 72C 
PLA1/PLA2 96C for 3min 
5 cycles of 95C for 3 min, 56C for 1 min 
31 cycles of 94C for 40 s, 55C for 40 s, 72C for 40s 
A final extension period of 5 min at 72C 
MTHFR C677T 94C for 5 min 
5 cycles of 94C for 60 s, 72C for 1 min 
25 cycles of 94C for 30 s, 59C for 40 s, 72C for 30s 
A final extension period of 10 min at 72C 
FVL, Factor V Leiden; MethyleneTetrahydrofolatereductase (MTHFR)   
 
RESULTS 
Clinical characteristics of patients 
Patients were recruited for this study from October 
2009 to December 2010. Table 3 shows patients’ 
characteristics (2).  
Twenty-seven (37.5%) patients were under 45 years of 
age. Thirteen (35.1%) patients of the study population were 
men with a mean age of 48.38 years, whereas the mean age 
of 24 women (64.9%) was 53 years (P¼NS). Patients with a 
previous history of PTE had a mean age of 47.6±20.3 years 
compared with 52.1±18.2 years in those without such 
history; no significant difference in this regard was 
observed (P¼0.42); in addition, there was no significant 
difference between patients with family history of PTE and 
patients with no family history (mean age of 42.6 versus 
52.3 years). 
 
Investigated genetic factors 
Twenty-four out of 37 (64.9%) patients compared with 
132 out of 306 (43.2%) controls were carrier of at least one 
thrombophilia polymorphism. A total number of 57 
mutations with a mean of 0.79 mutation were  observed in 
patients in contrast to 151 with a mean of 0.49 in controls  
(P<0.001). Table 4 summarizes data of investigated genetic 
factors. The prevalence of PLA2 was 27.8% in PTE patients 
versus 10.1% in controls (OR, 3.4; 95% CI, 1.08–6.44). In 
multivariate analysis with logistic regression, the OR for 
PLA2 was 3.43 (P<0.001). 
 
Polymorphisms in patients with previous or family 
history of venous  thromboembolism: 
Seven (19.4%) patients had a previous history of PTE 
with 18 investigated polymorphisms compared with 37 
polymorphisms in 57 patients without such history (2). 
 A total of 20 patients had PVO score<50% (54%) and 17 
had PVO score >50% (46%). FVL and FIIG20210A 
mutations and MTHFR C677T and PLA2 polymorphism 
were present in two (5.4%), one (2.7%), 16 (43.2%) and 10 
patients (27.02%), respectively. There was no significant 
difference between patients with PVO score >50% and 
those with PVO score <50% with respect to the presence of 
FVL [20% (n=3) and 17.6% (n=3) in patients with PVO 
score>50% and<50%, respectively] and the presence of 
PT20210A mutation [6.7% (n=1) and 5.9% (n=1) in patients 
with PVO score >50% and <50%, respectively].  
 
Table 3. Patient characteristics 
 
Characteristics of  PE patients  
No. of patients 37 
Mean age (years) 53.78  
 
Sex  
   Male N(%) 
   Female N(%) 
 
13(35.1%)  
24 (64.9%)  
Positive family history N(%) 6 (16.2%)  
Positive previous history N(%) 2 (5.4%)  
PE: pulmonary embolism. 
 
Patients with PLA2 polymorphism had more recurrent 
events than other patients (40 compared with 13.5%, 
P¼0.02). One patient with a previous PTE history was a 
carrier of FVL and MTHFR C677T as homozygous. 
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Table 4. Inherited thrombophilia polymorphisms in patients with PTE. 
 
Inherited risk factors All patients 
 with PTE (n=37) 
Controls (n=306) 
FVL 
Individuals (prevalence%)  
OR (95% CI)  
P-value  
 
2(5.4) 
2.51(0.72-8.83) 
NS* 
 
7(2.3) 
FII G20210A 
Individuals (prevalence%)  
OR (95% CI)  
P-value 
 
1(2.7)  
1.42 (0.146–13.88) 
NS* 
 
3(1) 
PLA2 
Individuals (prevalence%)  
OR (95% CI)  
P-value 
 
10 (27.02) 
 3.4 (1.8–6.44) 
 <0.001 
 
31 (10.1) 
 
MTHFR C677T 
Individuals (prevalence %)  
OR (95% CI)  
P-value 
 
16 (43.2)  
1.43 (0.85–2.40) 
NS* 
 
110 (35.9) 
 
CI, confidence interval; FVL, factor V Leiden; MTHFR:methylenetetrahydrofolatereductase; 
PE, pulmonary embolism; PTE, venous thromboembolism. * Not significant. 
 
 
DISCUSSION 
This study demonstrates that the prevalence of 
common inherited thrombophilic polymorphisms in our 
patients was neither similar to that in whites nor quite 
consistent with Asians. The findings of the present study 
show that some of the genetic thrombophilic 
polymorphisms enhanced the risk of PTE in our patients; 
however, the other investigated factors did not increase the 
risk. Among the patients with inherited thrombophilia, the 
highest prevalence was associated with having MTHFR 
C677T polymorphism (44.4%). The homozygous state of 
the polymorphism was significantly higher in patients than 
in controls (OR, 3.0;95% CI, 1.2–7.8), but no significant 
difference was seen in heterozygote carriers. The 
polymorphism is widespread among different populations, 
less frequent in some ethnic groups and more in others. It 
has been found in less than 2% of African-Americans and 
11.2% of Australians, which is comparable with the rate 
obtained for Europeans (13–17). Our control group shows 
the homozygosity frequency of 3.9%, which is less than 
that of whites. Although the prevalence is slightly higher 
in patients, we found no association between the 
polymorphism and PTE. This finding is different from the 
result of a study by Ivanov et al. (18) in which a lower 
prevalence in patients with pulmonary embolism was 
obtained. Polymorphism has been found to be equally 
distributed among thrombotic patients and controls in 
Turkey (12); however, it was identified, in agreement with 
our data, as a risk factor for VTE in Chinese/Thai 
populations (19). This polymorphism can increase the 
plasma level of Homocysteine  and hyperhomocysteinemia 
may have a pathogenic significance in venous and arterial 
thrombosis (16, 20, 21). It has been recently suggested that 
hyperhomocysteinemia may not be a direct cause of 
thrombosis, but a marker of systemic or endothelial 
oxidant stress and platelet activation (22). Our study also 
demonstrated that the prevalence of FVL was higher in 
PTE patients than in controls (5.6 versus 2.3%); however, 
this difference did not reach a significant level.  Many 
studies have indicated the role of FVL mutation in the 
cause of PTE. A prevalence of 23.5% has been found in 
patients with pulmonary embolism in Bulgaria (19), 
significantly higher than controls (23). Coppola et al. (24) 
and Biswas et al (25) found an association of homozygous 
FVL and some of the other rare abnormalities with more 
severe thrombotic phenotypes, but the common 
polymorphisms, such as heterozygous FVL, were 
associated with a lower thrombotic risk.  Although we 
found the homozygous to be more prevalent in our 
patients in contrast to controls (2.8 versus 0.3%), the 
difference was not significant. The prevalence has been 
suggested to be significantly higher in thrombotic patients 
but not in young patients with coronary artery disease in 
Turkey (16, 26, 27). The mutation was not found to be in 
association with PTE in a Chinese/Thai population (19).  
Our data seem to be in agreement with their population 
rather than whites. This disparity between different 
cohorts could be related to not only the number of patients 
but also national risk factors such as higher BMI or 
smoking that influences the non carriers. 
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The prevalence of FIIG20210A mutation was lower in 
our patients than that previously reported in whites and 
some other populations (5, 7, 26, 28, 29), as it was lower in 
non thrombotic controls as well (30, 31). Many studies have 
demonstrated the role of this polymorphism in the 
pathogenesis of PTE (5, 19); however, others found no 
relationship (19, 32). Our data are consistent with the latter, 
as we did not find a significant difference between patients 
and controls. 
The most striking finding was that the PLA2 
polymorphism was strongly associated with PTE 
(P<0.001). The frequency was about three times higher in 
patients with PTE than in controls (27.8 versus 10.1%), and 
this polymorphism was the only independent one 
associated with PTE in a multivariate analysis (P<0.001). 
Apparently, this polymorphism increases the affinity of 
glycoprotein IIb/IIIa receptor to fibrinogen and makes the 
platelets more susceptible to aggregation (2, 33), which 
could result in thrombosis. This finding is consistent with 
that of a study by Ivanov  et al. (18) on patients with 
pulmonary embolism and indicated the contribution of 
PLA2 polymorphism to PTE pathogenesis. Although not 
many studies are available concerning the role of PLA2 
allele in PTE (29), its role in arterial events has been shown 
in different studies (2, 34, 35). 
As demonstrated in our study, the coinheritance of 
more than one investigated genetic polymorphism 
increased the risk of PTE. Patients with more than one 
inherited risk factors had also more recurrent events. 
Although we did not find a significant difference 
between the age of patients and controls, the coinheritance 
of more than one inherited risk factor in patients with 
recurrent events influenced the age of patients (32 
compared with 51.1 years in all patients). This finding is 
consistent with that of Ivanov et al. (18) who found the first 
event in patients with pulmonary embolism with 
coinheritance of more than one risk factor before 45 years 
of age. However, we did not find the FVL/PLA2 
coinheritance to be more prevalent compared with their 
findings (18), which could be related to the lower 
prevalence of the FVL mutation in our patients. Risk of 
recurrent PTE events has been found to be more prevalent 
in patients with FVL or FIIG20210A mutation (35). Our 
data indicate that patients with a previous history of VTE 
have more thrombophilia mutation than those without 
such history. 
This is in agreement with those finding a higher risk of 
recurrence in thrombophilia carriers (18, 25). Previous 
studies have evaluated the risk of PTE in family members 
of patients. Couturaud et al. (36) and Pourghysari et al. (2) 
found the risk of thrombosis to be higher in the relatives of 
unprovoked PTE patients with FVL or FII G20210A 
mutation than in those without such mutations. We did not 
find a significant difference in the number of mutations in 
patients with and without the first-degree family history 
(data not shown). This finding can be related again to the 
lower prevalence of FVL and FII G20210A polymorphisms 
in our population. 
In this study, PVO score was used to assess the severity 
of PTE, which was found to be a reliable method of 
assessing the percentage of PVO (5). It was found that 
patients with PVO score>50% had significantly higher 
concentrations of factor VIIIc. It was also shown that 
patients with high factor-VIIIc concentrations (>150 IU) 
had an increased risk of experiencing severe PTE (PVOs 
>50%) (OR: 9.6; 95% CI:1.8–49.4). In the present study, the 
prevalence of FVL and PT20210A mutations was 14.9% but 
the prevalence of MTHFR C877T and PLA2 polymorphism 
was 26%, which are higher than the reported frequencies 
for healthy Turkish adults (10% and 2.6%, respectively (1). 
The data on PTE patients were higher than previous 
reports (3, 4), but were not associated with the severity of 
PTE.  
To date, there is no consensus about the duration of 
oral anticoagulant therapy in patients with high factor-
VIIIc concentrations. The authors believe that because a 
high factor-VIIIc concentration plays a distinct role in the 
recurrence of VTE and the severity of PTE, prolonged 
anticoagulation must be taken into consideration. In 
patients with PLA2 polymorphism, we recommend anti 
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platelet aggregation therapy after at least six months of 
anti coagulation therapy (2). 
 
CONCLUSION 
Our data suggest that presence of PLA2 is associated 
with an increased risk of PTE in the Iranian population. 
The association between recurrent events and 
coinheritance of more than one thrombophilic genetic risk 
factor shows that such carriers are at a higher risk of PTE. 
The events can occur in patients at younger ages. The 
clinical implication of this study concerns the carriers of 
PLA2, perhaps requiring a management different from that 
of other patients. Awareness of existing genetic risks could 
provide a prophylactic advantage regarding the control of 
acquired risk factors. Furthermore, testing for FVL or FII 
G20210A did not have the ability to predict the risk of 
thrombosis in this population. Lung perfusion scans were 
scored according to the percentage of PVO (32) (patients 
who had a PVO score > 50% were compared to those with 
(PVO score <50%).There was no significant difference 
between the patients with PVO score>50% and those with 
PVO score<50%, with regard to the presence of FVL and 
PT20210A mutation. However, patients with PVO 
score>50% had significantly higher platelet  glycoprotein 
IIb/IIIaPLA2 polymorphism  than those with PVO score 
<50%. 
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